PWMG
VRTX icon

Prestige Wealth Management Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Prestige Wealth Management Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$378K Sell
847
-11
-1% -$5.13K 0.07% 122
2025
Q4 		$389K Buy
858
+781
+1,014% +$337K 0.07% 124
2025
Q3 		$30.2K Hold
77
– – 0.01% 319
2025
Q2 		$34.3K Hold
77
– – 0.01% 294
2025
Q1 		$37.3K Sell
77
-35
-31% -$16.3K 0.01% 284
2024
Q4 		$45.1K Buy
112
+35
+45% +$16.2K 0.01% 267
2024
Q3 		$35.8K Hold
77
– – 0.01% 279
2024
Q2 		$36.1K Sell
77
-15
-16% -$6.51K 0.01% 253
2024
Q1 		$38.5K Sell
92
-11
-11% -$4.65K 0.01% 278
2023
Q4 		$41.9K Sell
103
-6
-6% -$2.22K 0.01% 261
2023
Q3 		$37.9K Hold
109
– – 0.01% 267
2023
Q2 		$38.4K Sell
109
-4
-4% -$1.35K 0.01% 288
2023
Q1 		$35.6K Sell
113
-6
-5% -$1.8K 0.01% 268
2022
Q4 		$34.4K Sell
119
-721
-86% -$220K 0.01% 289
2022
Q3 		$244K Buy
840
+637
+314% +$183K 0.07% 124
2022
Q2 		$57K Sell
203
-5
-2% -$1.34K 0.02% 226
2022
Q1 		$54K Buy
208
+2
+1% +$475 0.01% 237
2021
Q4 		$46K Buy
206
+57
+38% +$11.1K 0.01% 273
2021
Q3 		$27K Sell
149
-2
-1% -$390 0.01% 328
2021
Q2 		$30K Sell
151
-9
-6% -$1.88K 0.01% 302
2021
Q1 		$34K Buy
160
+12
+8% +$2.64K 0.01% 287
2020
Q4 		$35K Sell
148
-57
-28% -$13.1K 0.01% 283
2020
Q3 		$55K Buy
205
+13
+7% +$3.59K 0.02% 242
2020
Q2 		$55K Buy
192
+152
+380% +$41.2K 0.02% 213
2020
Q1 		$10K Buy
+40
New +$9.18K ﹤0.01% 388
2019
Q4 		– Sell
-2
Closed – – 680
2019
Q3 		$0 Buy
+2
New +$354 ﹤0.01% 645
2019
Q1 		– Sell
-125
Closed -$21K – 1128
2018
Q4 		$21K Buy
+125
New +$21.7K 0.02% 302

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Prestige Wealth Management Group's VRTX Position: Q1 2026 in Review

Prestige Wealth Management Group reduced its Vertex Pharmaceuticals (VRTX) stake by 1.3% in Q1 2026, selling an estimated $5.13K and leaving 847 shares worth $378K. The position accounts for 0.07% of the portfolio, ranked #122.

Prestige Wealth Management Group first reported a position in VRTX in Q4 2018 and has held it in 27 quarters since. The position peaked at $389K in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Prestige Wealth Management Group held 847 shares of Vertex Pharmaceuticals worth $378K as of Q1 2026.
  • Prestige Wealth Management Group sold 11 Vertex Pharmaceuticals shares in Q1 2026, an estimated $5.13K.
  • Vertex Pharmaceuticals made up 0.07% of Prestige Wealth Management Group's portfolio in Q1 2026, its #122 holding.
  • Prestige Wealth Management Group first reported a position in Vertex Pharmaceuticals in Q4 2018 and has held it in 27 quarters since.
  • Prestige Wealth Management Group's Vertex Pharmaceuticals position peaked at $389K in Q4 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Prestige Wealth Management Group's 13F filing for Q1 2026, filed 13 May 2026.